Quest Diagnostics (NYSE:DGX) Given New $166.00 Price Target at UBS Group

Quest Diagnostics (NYSE:DGX) had its target price hoisted by investment analysts at UBS Group from $165.00 to $166.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. UBS Group’s price objective would indicate a potential upside of 5.06% from the company’s previous close.

DGX has been the subject of several other research reports. Piper Sandler increased their target price on Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a research note on Monday, July 29th. Barclays increased their price objective on Quest Diagnostics from $154.00 to $168.00 and gave the company an “equal weight” rating in a research report on Wednesday. Truist Financial boosted their target price on shares of Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Citigroup increased their price target on shares of Quest Diagnostics from $165.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Robert W. Baird upgraded shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $157.00 to $182.00 in a report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of “Hold” and a consensus target price of $163.33.

Quest Diagnostics Trading Up 0.6 %

Shares of DGX stock opened at $158.00 on Wednesday. The business’s 50 day moving average is $153.05 and its two-hundred day moving average is $144.57. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. Quest Diagnostics has a 12 month low of $121.60 and a 12 month high of $160.95. The company has a market cap of $17.55 billion, a PE ratio of 21.27, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, October 22nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter last year, the firm posted $2.22 EPS. The business’s quarterly revenue was up 8.5% on a year-over-year basis. Equities analysts predict that Quest Diagnostics will post 8.89 EPS for the current year.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 1,990 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the sale, the senior vice president now owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.79% of the company’s stock.

Institutional Trading of Quest Diagnostics

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Quest Diagnostics by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock worth $1,853,151,000 after acquiring an additional 345,754 shares in the last quarter. Davis Selected Advisers raised its position in Quest Diagnostics by 0.4% in the 2nd quarter. Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock valued at $327,257,000 after purchasing an additional 9,665 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Quest Diagnostics by 6.5% in the second quarter. Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock worth $288,758,000 after purchasing an additional 129,395 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Quest Diagnostics by 2.1% during the third quarter. DekaBank Deutsche Girozentrale now owns 748,680 shares of the medical research company’s stock worth $115,621,000 after purchasing an additional 15,047 shares during the last quarter. Finally, Nuance Investments LLC increased its stake in shares of Quest Diagnostics by 13.1% in the first quarter. Nuance Investments LLC now owns 681,636 shares of the medical research company’s stock valued at $90,733,000 after buying an additional 79,152 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.